Sallman, D., Al Malki, M., Asch, A., Wang, E., Jurcic, J., Bradley, T., . . . Daver, N. (2023). Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study. American Society of Clinical Oncology.
Chicago Style (17th ed.) CitationSallman, DA, et al. Magrolimab in Combination with Azacitidine in Patients with Higher-risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. American Society of Clinical Oncology, 2023.
MLA引文Sallman, DA, et al. Magrolimab in Combination with Azacitidine in Patients with Higher-risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. American Society of Clinical Oncology, 2023.
警告：這些引文格式不一定是100％准確.